



Advanced Use of Adenoviral Vectors in Cancer and Gene Therapy

Guest Editor:

Dr. Dragomira Majhen

Ruder Bošković Institute, Division
of molecular biology, 10 000
Zagreb, Croatia

Deadline for manuscript
submissions:

closed (20 January 2022)

Message from the Guest Editor

Dear Colleagues,

In recent decades, we have witnessed major improvements in the therapy of patients with early-stage tumor due to new chemotherapy treatments, refined radiotherapy, and advanced operative techniques. However, serious limitations in classical cancer therapy still exist, and there is a need for innovative therapeutic approaches. The promising potential of adenoviral vectors is witnessed by the fact that the first-in-class gene therapy product to treat head and neck cancer was adenovirus coding for p53 that entered the commercial market in 2004. Nevertheless, further improvements in vector development technologies are essential to avoid activation of the endogenous signal transduction pathways and production of cytokines due to antivector immune responses. This Special Issue aims to collect the latest advances and state of the art of adenoviral vectors used in cancer and gene therapy. This includes but is not limited to virotherapy, oncolytic vectors, cancer targeting, cancer immune therapy, cancer vaccines, and novel adenoviral vectors that can infect and transduce target cell or tissue with high specificity.

Dr. Dragomira Majhen

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma